Global Enteric Disease Testing Market 2016-2020

  • ID: 3795241
  • Report
  • Region: Global
  • 65 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Alere
  • Biomerica
  • Cepheid
  • DiaSorin
  • Mobidiag
  • R-Biopharm
  • MORE
About Enteric Diseases

Enteric diseases are infections caused by ingested bacteria and viruses. Direct contact with contaminated feces or vomit is the secondary mode of contracting enteric ailments. Symptoms of enteric diseases include stomach pain, vomiting, diarrhea, nausea, weight loss, anorexia, and fever.

Enteric diseases may lead to stunted growth, malnutrition, and impaired cognitive development. Enteric disease testing is performed on individuals using rapid tests, culture tests, enzyme immunoassay tests, and immunoassay tests.

The analysts forecast the global enteric disease testing market to grow at a CAGR of 8.9% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global enteric disease testing market for 2016-2020. To calculate the market size, the author uses revenue generated from the sales of enteric disease testing products for Bacterial enterics (Clostridium difficile, Campylobacter, enterohemorrhagic Escherichia coli [EHEC], and Helicobacter pylori) and Viral enterics (Norovirus and Rotavirus)

The market is divided into the following segments based on geography:

- Americas
- APAC
- EMEA

The report, Global Enteric Disease Testing Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Alere
- bioMérieux
- Cepheid
- DiaSorin

Other prominent vendors
- BD
- Biomerica
- Coris BioConcept
- Meridian Bioscience
- Mobidiag
- Quidel
- Quest Diagnostics
- R-Biopharm
- Trinity Biotech
- Thermo Fisher Scientific

Market drivers
- Increase in adoption of molecular diagnostic testing

Market challenges
- Lack of awareness in underdeveloped countries

Market trends
- Shift from singleplex to multiplex testing

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Alere
  • Biomerica
  • Cepheid
  • DiaSorin
  • Mobidiag
  • R-Biopharm
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
PART 05: Reimbursement scenario: An overview

PART 06: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 07: Types of clinical diagnostic testing
  • Immunoassay testing
  • Molecular diagnostic testing
PART 08: Market segmentation by disease type
  • Bacterial enterics
  • Viral enterics
PART 09: Geographical segmentation
  • Geographical segmentation of global enteric disease testing market 2015-2020
  • Enteric disease testing market in Americas
  • Enteric disease testing market in EMEA
  • Enteric disease testing market in APAC
PART 10: Market drivers
  • High incidence of enteric diseases
  • Increase in adoption of molecular diagnostic testing
  • Availability of novel enteric testing platforms
PART 11: Impact of drivers

PART 12: Market challenges
  • Stringent regulatory environment
  • Lack of awareness in underdeveloped countries
  • Shortage of skilled technicians
PART 13: Impact of drivers and challenges

PART 14: Market trends
  • Development of novel NAAT for enteric disease testing
  • Shift from singleplex to multiplex testing
PART 15: Vendor landscape
  • Competitive scenario
  • Key vendor analysis
  • Other prominent vendors
PART 16: Appendix
  • List of abbreviations
PART 17: About the Author

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Reimbursement perspectives of healthcare entities
Exhibit 03: Global enteric disease testing market
Exhibit 04: Global enteric disease testing market 2015-2020 ($ millions)
Exhibit 05: Five forces analysis
Exhibit 06: Segmentation of global enteric disease testing market by microorganism 2015
Exhibit 07: Segmentation of global enteric disease testing market by geography 2015
Exhibit 08: Segmentation of global enteric disease testing market by geography 2020
Exhibit 09: Segmentation of global enteric disease testing market by geography 2015-2020
Exhibit 10: Enteric disease testing market in Americas 2015-2020 ($ millions)
Exhibit 11: Enteric disease testing market in EMEA 2015-2020 ($ millions)
Exhibit 12: Enteric disease testing market in APAC 2015-2020 ($ millions)
Exhibit 13: Impact of drivers
Exhibit 14: Impact of drivers and challenges
Exhibit 15: Alere: Key takeaways
Exhibit 16: bioMérieux: Key takeaways
Exhibit 17: Cepheid: Key takeaways
Exhibit 18: DiaSorin: Key takeaways
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Alere
  • Biomerica
  • Cepheid
  • DiaSorin
  • Mobidiag
  • R-Biopharm
  • MORE
New Report Released: - Global Enteric Disease Testing Market 2016-2020

The author of the report recognizes the following companies as the key players in the global enteric disease testing market: Alere, bioMérieux, Cepheid, and DiaSorin.

Other Prominent Vendors in the market are BD, Biomerica, Coris BioConcept, Meridian Bioscience, Mobidiag, Quest Diagnostics, R-Biopharm, Trinity Biotech, and Thermo Fisher Scientific.

Commenting on the report, an analyst from the research team said that the development of novel NAAT for enteric disease testing is an important trend that will lead to the growth of this market. Currently, PCR represents the gold standard for nucleic acid-based diagnostics. However, the need for variations in temperature increases power consumption and costs for laboratories. Currently, life sciences companies and academics have developed an isothermal amplification-based diagnostic method to circumvent the need for thermocyclers. Isothermal-based methods incorporate all the temperature-dependent steps of PCR by incorporating enzymes. For example, HDA, an isothermal technique of nucleic acid amplification utilizes helicase for complementing the denaturation step at a high temperature, and the entire amplification is completed under isothermal conditions in the range of 140°F-149°F. The method has been used for rapid diagnostics of the E. coli pathogen. This method reduces the cost of instrumentation due to the usage of helicase to separate DNA, which eliminates the need for a thermocycler.

According to the report, high incidence of enteric diseases is one of the key drivers to augment the growth prospects for this market. Enteric diseases are the most common cause of mortality worldwide, after cardiovascular and respiratory diseases. There has been a rise in the incidence of enteric diseases globally over the past decade. For example, each year two billion cases of diarrhea are reported worldwide, and 760,000 children aged five of below succumb to the disease in Sub-Saharan Africa region. The high incidence of enteric diseases increases the demand for screening and testing of infected victims. This, in turn, drives the adoption of diagnostic tests, thereby contributing to market growth.

Further, the report states that stringent regulatory environment are hampering the growth of the market. The regulatory requirements for in vitro diagnostic (IVD) devices worldwide are specific and call for the provision of in-depth technical information, as most of them are classified as class III medical devices. The waiting period for regulatory approvals in the US is long, which can add to developmental expenses and delay return on investment for companies that are involved in the development of the test. In Europe, the 98/79/EC of October 27 Directive is enforced on all in vitro medical diagnostic devices. Canada issues a license to medical products based on the risk category it falls under. This license is issued by the Health Canada authorities and the time taken to issue this license depends on the category of the product. These licenses are subject to annual renewal. Multinational players have to comply with various stringent regulatory conditions of each country in which they operate, which affects their turnaround time, capital expenditure, and profitability.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- Alere
- bioMérieux
- Cepheid
- DiaSorin
- BD
- Biomerica
- Coris BioConcept
- Meridian Bioscience
- Mobidiag
- Quest Diagnostics
- R-Biopharm
- Trinity Biotech
- Thermo Fisher Scientific
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll